Description of the Company and Summary of Significant Accounting Policies - Narrative (Details) $ / shares in Units, $ in Millions			3 Months Ended
	Aug. 23, 2023 shares	May 08, 2023 USD ($) $ / shares shares	Mar. 31, 2024 USD ($) Segment $ / shares shares	Apr. 02, 2023 USD ($)		Jan. 31, 2024	Jan. 01, 2024 USD ($)	Dec. 31, 2023 USD ($) $ / shares shares	May 31, 2023 shares	May 09, 2023 USD ($)	May 04, 2023 $ / shares	Apr. 20, 2023 ft²
Business Acquisition [Line Items]
Number of business segments | Segment			3
Common stock, par value (in dollars per share) | $ / shares		$ 0.01	$ 0.01					$ 0.01
Sales price per share (in CHF per share) | $ / shares											$ 22
Cash			$ 1,155					$ 1,382		$ 1,170
Common stock outstanding (in shares) | shares			1,914,698,483					1,915,057,000	1,716,160,000
Stock issued during exchange offer (in shares) | shares	1,533,830,450
Percent of common stock outstanding	80.10%
Separation-related adjustments			$ (183)
Total liabilities			16,662					$ 16,640
Separation-related costs			67	$ 98
Research and development costs			100	89
Area of property (in square feet) | ft²												290,000
Lease, term of contract (in years)						15 years
Finance lease, right-of-use asset, before accumulated amortization							$ 93
Finance lease, liabilities			$ 94				$ 93
Discount rate			4.75%
Right-of-use asset obtained in exchange for finance lease liability			$ 93
Fixed asset impairment			$ 68	0
Supplier finance program, payment timing, period			90 days
Supplier finance program, obligation, current			$ 267					$ 227
Net income			296	469	[1]
Revision of Prior Period, Reclassification, Adjustment
Business Acquisition [Line Items]
Total liabilities			96
Additional Paid-In Capital | Revision of Prior Period, Reclassification, Adjustment
Business Acquisition [Line Items]
Separation-related adjustments			(183)
Accumulated Other Comprehensive Loss | Revision of Prior Period, Reclassification, Adjustment
Business Acquisition [Line Items]
Separation-related adjustments			87
Variable Interest Entity, Primary Beneficiary
Business Acquisition [Line Items]
Total liabilities			35
Net income			2	0
Johnson & Johnson
Business Acquisition [Line Items]
Stock issued during exchange offer (in shares) | shares	190,955,435
Net Economic Benefit Arrangements | Parent
Business Acquisition [Line Items]
Net income			14	$ 0
Net payable			$ (32)
Consumer Health Business | Consumer Health Spinoff | Parent
Business Acquisition [Line Items]
Cash		$ 13,800
IPO
Business Acquisition [Line Items]
Shares issued in transaction (in shares) | shares		198,734,444
Proceeds from sale of stock		$ 4,200
Stock issuance costs		$ 131
Over-Allotment Option
Business Acquisition [Line Items]
Shares issued in transaction (in shares) | shares		25,921,884
Kenvue | Johnson & Johnson
Business Acquisition [Line Items]
Common stock outstanding (in shares) | shares		1,716,160,000
Percentage ownership after transaction		89.60%
Exchange of stock, percentage ownership after transaction	9.50%

[1] Prior to April 4, 2023, the Company operated as a segment of J&J and not as a separate entity. The Company’s financial statements prior to April 4, 2023 were prepared on a combined basis and were derived from J&J’s historical consolidated financial statements and accounting records as if the Company had been operated on a standalone basis. See Note 1, “Description of the Company and Summary of Significant Accounting Policies—Basis of Presentation,” for more information.